Rhumbline Advisers Reduces Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Rhumbline Advisers lessened its position in Option Care Health, Inc. (NASDAQ:OPCH) by 0.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 559,458 shares of the company’s stock after selling 5,060 shares during the quarter. Rhumbline Advisers’ holdings in Option Care Health were worth $19,553,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Murphy & Mullick Capital Management Corp purchased a new position in shares of Option Care Health in the 4th quarter worth about $26,000. Signaturefd LLC increased its stake in shares of Option Care Health by 487.9% in the 4th quarter. Signaturefd LLC now owns 1,211 shares of the company’s stock worth $28,000 after purchasing an additional 1,005 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in Option Care Health by 172.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company’s stock worth $40,000 after acquiring an additional 1,099 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in Option Care Health by 21.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company’s stock worth $43,000 after buying an additional 332 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in Option Care Health during the fourth quarter valued at $47,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on OPCH shares. UBS Group upgraded Option Care Health from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. JPMorgan Chase & Co. increased their price objective on shares of Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. Barrington Research restated an “outperform” rating and issued a $38.00 price target on shares of Option Care Health in a report on Wednesday, April 30th. Finally, JMP Securities reiterated a “market outperform” rating and set a $36.00 price objective on shares of Option Care Health in a report on Tuesday, April 22nd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Option Care Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.50.

Option Care Health Trading Down 0.8%

Shares of OPCH stock opened at $31.90 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The firm has a market cap of $5.22 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 2.30 and a beta of 0.74. The company has a 50-day moving average of $32.42 and a two-hundred day moving average of $29.95. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.26 billion. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.26 earnings per share. On average, analysts predict that Option Care Health, Inc. will post 1.22 EPS for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.